Document is current

Article History

Received: 22 June 2023

Accepted: 2 August 2023

First Online: 12 September 2023

Declarations

:

: E.A. Macklin reports receiving grants to his institution on his behalf from AI Therapeutics, Alector, Amylyx, Biohaven, Calico Life Sciences, Chase Therapeutics, Clene Nanomedicine, Denali Therapeutics, Mitsubishi Tanabe Pharma America, Prilenia, Revalesio, Seelos Therapeutics, and UCB Ra Pharma; serving on Steering Committees for Stoparkinson Healthcare and UCB; serving on Data Monitoring Committees for NeuroSense, Novartis, and Sanofi; and serving on advisory boards for Alector, Bial Biotech, Cortexyme, Enterin, InTrance, nQ Medical, and Partner Therapeutics. Prof. Schwarzschild serves on the scientific advisory boards of Michael J. Fox Foundation for Parkinson’s Research SAB (New York, NY) [2017-2019], Cure Parkinson’s Trust foundation Linked Clinical Trials program SAB (London, UK) [~2012- ], Eli Lilly & Company (clinical trial DSMB service) [2018-2021], Prevail Therapeutics (clinical advisory board) [2018-2019], Parkinson’s Foundation (Genetics initiative advisory board) [2018- ], X-linked Dystonia Parkinsonism Clinical Center [2018- ], Denali Therapeutics (clinical advisory board) [2019], NIH/NIA-funded TOPAZ trial SC via Sutter Health, NIH/NINDS-funded SPARX3 trial SC, STEPWISE trial SC via Farmer Family Foundation award, Bial Pharmaceuticals (via the Parkinson Study Group), Biogen (via the Parkinson Study Group) [2021- ], UCB (via the Parkinson Study Group) [2022]. He received fees for speaking by Denali Therapeutics (2019), all other speaker fees were fore non-profit entities (Krembil Conference, World Parkinson Congress, Parkinson Study Group, Cure Parkinson’s Trust). Moreover, he performed consultancies for Harvard University (Parkinson’s disease case reviews and epidemiology research) [~2002- ], Eli Lilly & Company (clinical trial DSMB service) [2018-2021], Prevail Therapeutics, Inc (New York City) [2018-2019], Denali Therapeutics (Nice, France) [2019], Parkinson Study Group services to nQ Medical (Cambridge, MA) [2019], Chase Therapeutics (Washington, DC) [2019], Partner Therapeutics (virtual) [2020], Bial (virtual) [2021- ], Biogen (virtual) [2021- ], UCB (virtual) [2022- ]. He received research support by NIH R01 NS110879 (PI) 08/01/19 – 05/31/24, NIH U01 NS107009 (a PI) 07/01/18 to 04/30/23, NIH R01NS102735 (Co-Investigator [Xiqun Chen, PI]) 4/1/18 - 3/31/23, NIH R13 NS111953 (PI) 04/01/19 – 03/31/22, IH R13 (co-I) 2022-2023, NIH U01 NS090259 (PI) 9/1/2015 to 6/30/2020, NIH R01 (Collaborator [A. Ascherio, PI]). Prof. Schwarzschild received grant support via his institution (MGH) on projects for which he is the Principal Investigator: (1) Michael J. Fox Foundation/ASAP (2) Parkinson’s Foundation (3) Farmer Family Foundation. Prof. Schwarzschild served on the editorial advisory board of the Journal of Adenosine and Caffeine Research and Parkinsonism and Related Disorders. Prof. Bloem, currently serves as the co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for UCB, Kyowa Kirin, Zambon and the Critical Path Institute (paid to the Institute), has received fees for speaking at conferences from AbbVie, Biogen, UCB, Zambon, Roche, GE Healthcare, Oruen and Bial (paid to the Institute), and has received research support from the Netherlands Organization for Health Research and Development, the Michael J Fox Foundation, UCB, the Stichting Parkinson Fonds, Hersenstichting Nederland, de Stichting Woelse Waard, Stichting Alkemade-Keuls, de Maag Lever Darm Stichting, Parkinson NL, Davis Phinney Foundation, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, Nothing Impossible and the Parkinson Vereniging. Other authors have no competing interests to report.

: The study is performed in accordance with the Declaration of Helsinki. Ethical approval was granted by the medical ethical committee of Arnhem-Nijmegen (NL75501.091.20) and the STEPWISE Parkinson study is registered at clinicaltrials.gov (NCT04848077) on April 19 2021. All participants provided informed-consent.

: NA.